Company to host conference call and webcast on Thursday, November 7 th at 8:30am EDT LYON, France, October 24, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter
LYON, France, October 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the Company’s proprietary Focal One ® robotic high-intensity focused ultrasound (HIFU)
First Unfold AI ® -Assisted Focal One procedures successfully performed at the UCLA School of Medicine FDA-cleared Unfold AI enables urologists to provide tailored, patient-specific Robotic HIFU ablation for prostate cancer patients EDAP and Avenda
LYON, France, August 29, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate in a fireside chat and host 1x1 investor meetings at the H.C.
Record Q2 2024 total worldwide revenue of EUR 15.8 million (USD 17.0 million) increased 10.6% over Q2 2023 Record first half 2024 total worldwide revenue of EUR 30.7 million (USD 33.1 million) increased 5.6% over first half 2023 Strong Q2 2024 U.S.
Company to host conference call and webcast on Wednesday, August 28 th at 8:30am EDT LYON, France, August 7, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter
Semi-Live Focal One Procedure to be Conducted on August 15 t h at 5:00 pm (KST) LYON, France, August 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the Company’s leading robotic HIFU technology platform, Focal One, will be featured at
Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and 2 studies in patients with deep infiltrating endometriosis At three months post procedure, the study’s primary endpoint of reduced acute pelvic pain in the HIFU
PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to its Board of Directors. “We are pleased to welcome Fran Schulz to our Board of Directors," said Marc
New appointments bring significant commercial experience with a focus on growing key strategic markets Expands executive leadership in growing disruptive, robotics-based capital equipment in both Urology and Gynecology therapeutic applications LYON, France, June 3, 2024 - EDAP TMS SA (Nasdaq:
